Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study

被引:197
作者
Steinberg, JS
Sadaniantz, A
Kron, J
Krahn, A
Denny, DM
Daubert, J
Campbell, WB
Havranek, E
Murray, K
Olshansky, B
O'Neill, G
Sami, M
Schmidt, S
Storm, R
Zabalgoitia, M
Miller, J
Chandler, M
Nasco, EM
Greene, HL
机构
[1] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Div Cardiol, New York, NY 10025 USA
[2] Columbia Univ, New York, NY USA
[3] Miriam Hosp, Providence, RI 02906 USA
[4] Axio Res Corp, Seattle, WA USA
[5] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
[6] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[7] Geisinger Med Ctr, Danville, PA 17822 USA
[8] W Virginia Univ Hosp, Morgantown, WV USA
[9] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada
[10] Sutter Inst Med Res, Sacramento, CA USA
[11] Univ Iowa, Iowa City, IA USA
[12] Vanderbilt Univ, Nashville, TN USA
[13] Denver Gen Hosp, Denver, CO USA
[14] St Thomas Hosp, Nashville, TN USA
[15] Univ Rochester, Rochester, NY USA
[16] River Cities Cardiol, Jeffersonville, IN USA
[17] London Hlth Sci Ctr, London, ON, Canada
[18] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
关键词
atrium; fibrillation; antiarrhythmia agents; survival;
D O I
10.1161/01.CIR.0000118472.77237.FA
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Expectations that reestablishing and maintaining sinus rhythm in patients with atrial fibrillation might improve survival were disproved in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. This report describes the cause-specific modes of death in the AFFIRM treatment groups. Methods and Results-All deaths in patients enrolled in AFFIRM underwent blinded review by the AFFIRM Events Committee, and a mode of death was assigned. In AFFIRM, 2033 patients were randomized to a rhythm-control strategy and 2027 patients to a rate-control strategy. During a mean follow-up of 3.5 years, there were 356 deaths in the rhythm-control patients and 310 deaths in the rate-control patients (P=0.07). In the rhythm-control group, 129 patients (9%) died of a cardiac cause, and in the rate-control group, 130 patients (10%) died (P=0.95). Both groups had similar rates of arrhythmic and nonarrhythmic cardiac deaths. The numbers of vascular deaths were similar in the 2 groups: 35 (3%) in the rhythm-control group and 37 (3%) in the rate-control group (P=0.82). There were no differences in the rates of ischemic stroke and central nervous system hemorrhage. In the rhythm-control group, there were 169 noncardiovascular deaths (47.5% of the total number of deaths), whereas in the rate-control arm, there were 113 noncardiovascular deaths (36.5% of the total number of deaths) (P=0.0008). Differences in noncardiovascular death rates were due to pulmonary and cancer-related deaths. Conclusions-Management of atrial fibrillation with a rhythm-control strategy conferred no advantage over a rate-control strategy in cardiac or vascular mortality and may be associated with an increased noncardiovascular death rate.
引用
收藏
页码:1973 / 1980
页数:8
相关论文
共 29 条
[11]   ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:: Executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) [J].
Fuster, V ;
Rydén, LE ;
Asinger, RW ;
Cannom, DS ;
Crijns, HJ ;
Frye, RL ;
Halperin, JL ;
Kay, GN ;
Klein, WW ;
Lévy, S ;
McNamara, RL ;
Prystowsky, EN ;
Wann, LS ;
Wyse, DG ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Russell, RO ;
Smith, SC ;
Klein, WW ;
Alonso-Garcia, A ;
Blomström-Lundqvist, C ;
De Backer, G ;
Flather, M ;
Hradec, J ;
Oto, A ;
Parkhomenko, A ;
Silber, S ;
Torbicki, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :1231-1265
[12]   Maintenance of sinus rhythm in patients with atrial fibrillation - An AFFIRM substudy of the first antiarrhythmic drug [J].
Greene, HL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) :20-29
[13]   LEFT-VENTRICULAR DYSFUNCTION DUE TO ATRIAL-FIBRILLATION IN PATIENTS INITIALLY BELIEVED TO HAVE IDIOPATHIC DILATED CARDIOMYOPATHY [J].
GROGAN, M ;
SMITH, HC ;
GERSH, BJ ;
WOOD, DL .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (19) :1570-1573
[14]   Inhibition of metastases by anticoagulants [J].
Hejna, M ;
Raderer, M ;
Zielinski, CC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (01) :22-36
[15]   Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT [J].
Julian, DG ;
Camm, AJ ;
Frangin, G ;
Janse, MJ ;
Munoz, A ;
Schwartz, PJ ;
Simon, P .
LANCET, 1997, 349 (9053) :667-674
[16]   THE NATURAL-HISTORY OF ATRIAL-FIBRILLATION - INCIDENCE, RISK-FACTORS, AND PROGNOSIS IN THE MANITOBA FOLLOW-UP-STUDY [J].
KRAHN, AD ;
MANFREDA, J ;
TATE, RB ;
MATHEWSON, FAL ;
CUDDY, TE .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 (05) :476-484
[17]  
LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
[18]   STROKE PREVENTION IN ATRIAL-FIBRILLATION STUDY - FINAL RESULTS [J].
MCBRIDE, R .
CIRCULATION, 1991, 84 (02) :527-539
[19]   Health outcomes associated with antihypertensive therapies used as first-line agents - A systematic review and meta-analysis [J].
Psaty, BM ;
Smith, NL ;
Siscovick, DS ;
Koepsell, TD ;
Weiss, NS ;
Heckbert, SR ;
Lemaitre, RN ;
Wagner, EH ;
Furberg, CD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (09) :739-745
[20]  
Richardson DW, 1999, J AM COLL CARDIOL, V34, P1552